Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

1

CD73 is a key enzyme in the adenosine-mediated immunosuppressive pathway, making it a target for cancer immunotherapy.
2

Monoclonal antibodies CR201 and CR202 were developed to inhibit CD73 enzymatic activity and promote receptor internalization.
3

CR201 targets the C-terminal domain of CD73, while CR202 targets the N-terminal domain, enabling distinct functional profiles.
4

Both antibodies restored T-cell proliferation and IFN-γ production, and significantly suppressed tumor growth in vivo.
5

CR201 and CR202 demonstrate potential as next-generation therapeutic candidates for overcoming adenosine-mediated immunosuppression.

Frontiers In Immunology

by Miao Zhang, Haibin Yuan, Xindi Pan, Xian Li, Zichen Wang, Shuping Zhang, Zhigang Gu, Biao Hu, Xuedong Qu, Qian Wang, Xiangguo Gu, Bo Wang, Yu Cao, Guilin Mu, Guangbo Kang, Ario de Marco, Xiangshan Zhou, He Huang
June 10, 2026

1